KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Goodwill & Intangibles (2016 - 2019)

Historic Goodwill & Intangibles for Arbutus Biopharma (ABUS) over the last 7 years, with Q2 2019 value amounting to $66.3 million.

  • Arbutus Biopharma's Goodwill & Intangibles fell 1825.86% to $66.3 million in Q2 2019 from the same period last year, while for Jun 2019 it was $66.3 million, marking a year-over-year decrease of 1825.86%. This contributed to the annual value of $66.3 million for FY2018, which is 2012.26% down from last year.
  • According to the latest figures from Q2 2019, Arbutus Biopharma's Goodwill & Intangibles is $66.3 million, which was down 1825.86% from $66.3 million recorded in Q1 2019.
  • In the past 5 years, Arbutus Biopharma's Goodwill & Intangibles ranged from a high of $546.1 million in Q2 2015 and a low of $66.3 million during Q3 2018
  • Moreover, its 5-year median value for Goodwill & Intangibles was $123.8 million (2016), whereas its average is $242.1 million.
  • Examining YoY changes over the last 5 years, Arbutus Biopharma's Goodwill & Intangibles showed a top increase of 556.55% in 2016 and a maximum decrease of 7596.67% in 2016.
  • Over the past 5 years, Arbutus Biopharma's Goodwill & Intangibles (Quarter) stood at $515.2 million in 2015, then tumbled by 75.97% to $123.8 million in 2016, then tumbled by 32.95% to $83.0 million in 2017, then dropped by 20.12% to $66.3 million in 2018, then changed by 0.0% to $66.3 million in 2019.
  • Its last three reported values are $66.3 million in Q2 2019, $66.3 million for Q1 2019, and $66.3 million during Q4 2018.